Zimmer Biomet Holdings (ZBH) Earnings Analysis

Zimmer Biomet Holdings (ZBH) delivered mixed results in Q2 FY2026 on revenue of $2.2B versus the $2.1B estimate (+4.8% YoY) and EPS of $2.07. The next Zimmer Biomet Holdings (ZBH) earnings date is Nov 4, 2026. Below is the full Zimmer Biomet Holdings earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.

Zimmer Biomet Holdings (ZBH) Earnings Analysis — key stats

Next earnings dateNov 4, 2026
Latest reported quarterQ2 FY2026
Earnings verdictMixed
EPS beat rate4 of last 8 (quarters above estimate)
Avg next-day move±8.0% (over the last 8 reports)
Post-earnings directionUp 4 / Down 4 (of the last 8 reports)
Implied move (next report)±5.3% (options-derived · into Nov 4, 2026)
Institutional ownership102.7% (13F as of 2026-06-30)
Top 10 holders56.5% (of shares outstanding)
Insider activity2 buys / 4 sells (recent Form 4 filings)
Revenue$2.2B (vs $2.1B est · +2.0% surprise · +4.8% YoY)
EPS$2.07 (vs $2.01 est · +3.0% surprise · +33.8% YoY)
Share price$98.66 (-0.1%)
Market cap$18.8B

Zimmer Biomet Holdings (ZBH) Earnings Analysis — beat / miss history

QuarterRevenueEPSEPS surpriseNext-day moveVerdict
Q3 FY2026$2.2B vs $2.1B est$2.07 vs $2.01 est+3.0%+1.4%Mixed
Q2 FY2026$2.1B vs $2.1B est$2.09 vs $1.86 est+12.4%-13.5%Mixed
Q1 FY2026$2.2B vs $2.2B est$2.42 vs $2.38 est+1.7%+6.6%In line
Q4 FY2025$2.0B vs $2.0B est$1.90 vs $1.87 est+1.6%-14.2%In line
Q3 FY2025$2.1B vs $2.1B est$2.07 vs $1.98 est+4.5%+8.9%Mixed
Q2 FY2025$1.9B vs $1.9B est$1.81 vs $1.77 est+2.3%-9.9%Mixed
Q1 FY2025$2.0B vs $2.0B est$2.31 vs $2.30 est+0.4%-6.8%In line
Q4 FY2024$1.8B vs $1.8B est$1.74 vs $1.74 est+0.0%+2.9%In line

Top institutional holders

Holder% outstandingSharesValueQoQ change
Dodge & Cox12.6%24.1M$2.1B+2.5%
Blackrock, INC.8.1%15.6M$1.3B+1.8%
Harris Associates L P6.6%12.7M$1.1B-1.7%
Vanguard Capital Management LLC6.6%12.6M$1.1B-1.2%
Capital International Investors6.3%12.2M$1.0B+33.6%
State Street Corp4.6%8.9M$766.3M+0.6%
Vanguard Portfolio Management LLC4.4%8.4M$726.7M-2.4%
Geode Capital Management, LLC2.8%5.3M$458.7M-0.6%
Price T Rowe Associates INC /Md/2.5%4.8M$413.0M-40.0%
Invesco Ltd.2.1%4.0M$342.6M+10.4%

Recent insider transactions

InsiderRoleDateTypeSharesValue
Campbell Gary Craigofficer: President, Americas2026-10-01Buy1K—
Campbell Gary Craigofficer: President, Americas2026-10-01Sell1K—
Campbell Gary Craigofficer: President, Americas2026-10-01Buy2K—
Campbell Gary Craigofficer: President, Americas2026-10-01Sell480$42442
Campbell Gary Craigofficer: President, Americas2026-10-01Sell932$82407
Campbell Gary Craigofficer: President, Americas2026-10-01Sell2K—
Hatcher Brian Matthewofficer: President, Recon, SET, CMFT2026-10-01Other0—
Hatcher Brian Matthewofficer: President, Recon, SET, CMFT2026-10-01Other1K$156374

What you'll find

Frequently asked questions

When is Zimmer Biomet Holdings's next earnings date?
Zimmer Biomet Holdings's (ZBH) next scheduled earnings date is Nov 4, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Zimmer Biomet Holdings (ZBH) beat or miss earnings?
In Q2 FY2026, Zimmer Biomet Holdings (ZBH) posted mixed results — revenue of $2.2B versus the $2.1B estimate (+2.0% surprise) and EPS of $2.07 versus $2.01 expected (+3.0% surprise). Magnisto decodes every Zimmer Biomet Holdings (ZBH) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Zimmer Biomet Holdings beat earnings estimates?
Over its last 8 reported quarters, Zimmer Biomet Holdings (ZBH) beat Wall Street EPS estimates 4 times, most recently a mixed result in Q3 FY2026. Magnisto tracks every Zimmer Biomet Holdings (ZBH) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Zimmer Biomet Holdings stock move after earnings?
Over its last 8 quarterly reports, Zimmer Biomet Holdings (ZBH) moved an average of ±8.0% the day after earnings — ranging from -14.2% (Q4 FY2025) to +8.9% (Q3 FY2025). The stock rose after 4 of those 8 reports and fell after 4. Heading into its next report on Nov 4, 2026, options-implied volatility is pricing in a move of roughly ±5.3% (derived). Magnisto tracks the realized post-earnings move for every Zimmer Biomet Holdings (ZBH) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Zimmer Biomet Holdings?
Institutions hold about 102.7% of Zimmer Biomet Holdings's (ZBH) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Dodge & Cox (12.6%), Blackrock, INC. (8.1%), Harris Associates L P (6.6%). Magnisto lists Zimmer Biomet Holdings's (ZBH) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Zimmer Biomet Holdings (ZBH)?
In the most recent Form 4 filings Magnisto tracks, Zimmer Biomet Holdings (ZBH) insiders recorded 2 purchases and 4 sales — net selling. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Zimmer Biomet Holdings (ZBH) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Zimmer Biomet Holdings (ZBH), anchored to the current $98.66 share price, so you can weigh the bull, base and bear cases for Zimmer Biomet Holdings side by side.
Is Zimmer Biomet Holdings (ZBH) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Zimmer Biomet Holdings fits your own thesis and risk profile. This is research, not investment advice.

Related stocks

Educational research, not investment advice. Figures are illustrative and may be delayed.